Detalhes bibliográficos
Ano de defesa: |
2018 |
Autor(a) principal: |
ROCHA, Viviane Chaves de Carvalho
 |
Orientador(a): |
FARIA, Manuel dos Santos
 |
Banca de defesa: |
FARIA, Manuel dos Santos
,
FURTADO NETO, João Francisco
,
BECKMAN, Adriana Maria Guimarães Sá
,
SILVA, Marcelo Magalhães
,
BRITO, Luciane Maria Oliveira |
Tipo de documento: |
Dissertação
|
Tipo de acesso: |
Acesso aberto |
Idioma: |
por |
Instituição de defesa: |
Universidade Federal do Maranhão
|
Programa de Pós-Graduação: |
PROGRAMA DE PÓS-GRADUAÇÃO EM SAÚDE DO ADULTO E DA CRIANÇA/CCBS
|
Departamento: |
DEPARTAMENTO DE MEDICINA I/CCBS
|
País: |
Brasil
|
Palavras-chave em Português: |
|
Palavras-chave em Inglês: |
|
Área do conhecimento CNPq: |
|
Link de acesso: |
https://tedebc.ufma.br/jspui/handle/tede/2338
|
Resumo: |
The consensus in the literature is that the hypothalamic–pituitary axis should be investigated with stimulus tests only for pituitary lesions larger than 1 cm. Pituitary tumors smaller than 1 cm may present deficiencies of growth hormone and cortisol to the stimulus tests. We evaluated the response of growth hormone and cortisol to the glucagon test of 3 h duration (fixed dose: 1mg and 1,5mg Glucagon on 90 kg and ≥ 90kg, respectively) in 40 patients with pituitary lesions smaller than 1 cm, followed by an insulin tolerance test (ITT) to confirm the deficiencies. In the glucagon test, 3.7% (n=1) of the microprolactinomas did not respond to growth hormone (<3 ng/mL) and 77.8% (n= 21) presented cortisol values >18 μg/dL, while 37.5% of the nonfunctioning microadenomas had a sub-growth hormone (GH deficiency). All 40 patients had growth hormone value >1 ng/mL. Deficiencies of growth hormone and cortisol were not confirmed by the ITT in patients who had on Glucagon Test deficiencies . Our findings demonstrate that the glucagon test has a high number of false positive results with higher cutoff values. The glucagon test has been shown to be a safe option when there is a contraindication to the ITT. Stimulus tests should not be routinely indicated for evaluation of the hypothalamic–pituitary axis in cases of lesions smaller than 1 cm, except in cases where there are metabolic or clinical alterations suggestive of such deficiencies or progressive decreases of insulin-like growth factor 1 (IGF-1) and cortisol during routine follow-up of these patients. There is a need for adequate cutoffs for both growth hormone and cortisol. |